Do weight-loss drugs reduce long-term sickness leave without raising employment or income?
Core argument: GLP-1 treatment reduces long-term sickness leave by 0.95 percentage points, a 17.3% decline relative to the pre-initiation mean of 5.5%, according to estimates from linked Danish administrative data and a matched stacked difference-in-differences design.
This paper provides new evidence on the economic consequences of GLP-1 treatment using linked Danish administrative data and a matched stacked difference-in-differences design. Comparing early Ozempic initiators to observably similar patients who initiate four years later, we find that GLP-1 treatment reduces long-term sickness leave by 0.95 percentage points, corresponding to a 17.3% decline relative to the pre-initiation mean of 5.5% (Figure 2). This effect grows from roughly 0.8 percentage points in the first two post-initiation years to about 1.1 percentage points in years 3 and 4 (Figure 2) and is accompanied by declines in emergency department encounters and cardiovascular medication use, consistent with sustained treatment exposure and gradual improvements in underlying health. [There are no statistically significant or economically meaningful effects on employment or total income over four years.] Yet, even in their absence, GLP-1 treatment generates meaningful fiscal spillovers by reducing prolonged sickness absence, valued at 1.3–1.5% of annual labor income per employed individual. [The long-term sickness-leave results are robust across alternative specifications and comparison groups (Figure 3).]

